Jazz Pharmaceuticals plc — Q3 2023 Form 10-Q
Business context and reporting period. Global biopharmaceutical company focused on neuroscience and oncology, with marketed products including Xywav, Xyrem, Epidiolex/Epidyolex, Rylaze, Zepzelca, Defitelio and Vyxeos. This unaudited quarterly filing covers the three and nine months ended September 30, 2023. Amounts below are in U.S. dollars unless noted.
Key financial results
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Total revenue | $972.1m | $940.7m | $2,822.3m | $2,687.3m |
| Operating income | $172.4m | $24.8m | $456.1m | $197.9m |
| Net income (loss) | $146.8m | $(19.6)m | $320.7m | $16.7m |
| Diluted earnings (loss) per share | $2.14 | $(0.31) | $4.67 | $0.26 |
| Net interest expense | $71.5m | $80.2m | $219.1m | $214.1m |
| Income tax benefit | $47.2m | $43.0m | $86.8m | $58.6m |
- Q3 revenue increased 3%; product sales were essentially flat, while royalties and contract revenues rose to $33.7m, including $28.9m in royalties from high-sodium oxybate authorized generics. Nine-month revenue increased 5%.
- Reported gross margin as a percentage of product sales was 89.1% in Q3 and 88.1% for the nine-month period, versus 85.7% and 86.0%, respectively, in 2022. The improvement primarily reflected lower acquisition-accounting inventory fair-value step-up expense.
- Cash and cash equivalents were $1,335.7m and investments were $250.0m at September 30, 2023. Nine-month operating cash flow was $924.7m, compared with $930.0m a year earlier. Cash increased $454.2m during the period.
- Debt carrying value was $5,715.3m, including $604.5m classified as current; scheduled principal outstanding was $5,805.3m. The $575m 2024 Notes mature in August 2024. The company reported $500m available under its revolving credit facility.
- Current assets were $3,245.8m and current liabilities were $1,573.3m. Inventory was $611.8m, including $348.1m of acquired GW inventory fair-value step-up.
Material changes versus prior periods
- Xywav sales rose 30% in Q3 to $331.6m and 38% for nine months to $936.0m, supported by increased patient adoption, including growth in idiopathic hypersomnia.
- Xyrem sales fell 51% in Q3 to $125.1m and 40% for nine months to $463.0m, reflecting patient transition to Xywav and high-sodium oxybate competition. The company reported approximately 12,050 patients taking Xywav at quarter-end.
- Epidiolex/Epidyolex sales grew 9% in Q3 and 14% for nine months. Oncology sales rose 17% in Q3 and 14% for nine months, led by Rylaze, up 43% and 46%, respectively.
- Q3 R&D expense increased 57% to $234.4m; nine-month R&D rose 51% to $633.1m, primarily reflecting clinical work including zanidatamab. SG&A declined 14% in Q3 and 8% for nine months.
- Q3 2022 included a $133.6m impairment charge related to discontinuing the nabiximols program, contributing to the year-over-year improvement in operating income and net income. Tax benefits and jurisdictional income mix also affect comparisons.
- For nine months, share repurchases totaled $170.0m for 1.3m shares. Debt repayments were $23.3m, versus $574.3m in the comparable 2022 period.
Outlook, commentary and risks
- Management expected 2023 total product sales to exceed 2022, supported by Xywav, Epidiolex and oncology growth, partly offset by further Xyrem declines. It expected royalty and contract revenues to increase, mainly from oxybate authorized-generic royalties.
- Management expected 2023 SG&A to decrease, R&D to increase as clinical programs advance, cost of product sales to decrease with lower inventory step-up expense, amortization to be broadly in line with 2022, and net interest expense to increase. The filing provides no specific full-year revenue or earnings guidance figures.
- The company said existing cash, expected operating cash flow and the revolver should fund operations and obligations for the foreseeable future, while noting substantial debt and the risk that weaker product sales or other adverse developments could impair liquidity or debt service capacity.
- Key commercial risks include competition from Avadel’s Lumryz and authorized generics, pricing and reimbursement pressure, and continued dependence on oxybate products. Management also cited generic challenges to Epidiolex, clinical and regulatory uncertainty, and reliance on single-source suppliers for most products and APIs.
- Material legal matters include Xyrem antitrust litigation, patent disputes involving Avadel and generic applicants for Xywav and Epidiolex, and the company’s suit challenging FDA’s approval of Lumryz. The Xyrem antitrust classes were preliminarily certified; trial was scheduled for October 2024. The company’s and opposing parties’ summary-judgment motions in the FDA case remained pending.
- After quarter-end, Jazz disclosed settlements with Alkem concerning Xyrem generics and Padagis concerning Epidiolex generics; the latter’s specific terms were confidential. Luxembourg tax authorities proposed approximately $23.7m in additional tax assessments, which Jazz disputes and is contesting.
Most important facts for investors to verify
- Whether Xywav growth and high-sodium oxybate royalties can offset continued Xyrem erosion and new competition.
- Progress and potential commercial impact of Lumryz, authorized generics, generic patent challenges and related litigation outcomes.
- Execution of pipeline programs, especially zanidatamab, and the effect of elevated R&D spending on profitability and cash generation.
- Debt maturities, refinancing or repayment plans, and capacity to reduce leverage while funding development and capital returns.
- Exposure to customer concentration: ESSDS represented 49% of nine-month revenue and 45% of gross receivables at quarter-end.
- Potential financial effects of legal proceedings, the disputed Luxembourg tax assessments, and other contingencies; the filing does not provide a clear estimate of potential Xyrem litigation losses.